Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C

Authors

  • Andrea L. Cox,

    1. Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD
    2. Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
    Search for more papers by this author
  • Timothy Mosbruger,

    1. Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD
    Search for more papers by this author
  • Georg M. Lauer,

    1. Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA
    Search for more papers by this author
  • Drew Pardoll,

    1. Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD
    2. Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
    3. Department of Molecular Biology and Genetics, Johns Hopkins Medical Institutions, Baltimore, MD
    4. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD
    Search for more papers by this author
  • David L. Thomas,

    1. Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD
    2. Department of Epidemiology, Johns Hopkins Medical Institutions, Baltimore, MD
    Search for more papers by this author
  • Stuart C. Ray

    Corresponding author
    1. Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD
    2. Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
    • Viral Hepatitis Center, 1503 E. Jefferson St., Baltimore, MD 21231
    Search for more papers by this author
    • fax: 410-614-7564.


  • Potential conflict of interest: Nothing to report.

Abstract

We comprehensively studied the cellular immune response during acute human hepatitis C virus (HCV) infection by monthly prospective sampling of persons at high risk of infection. In 19 of 23 subjects, interferon-gamma–secreting T cells specific for 1 or more peptides spanning the entire HCV polyprotein were detected 1 to 3 months after infection. The median time to development of interferon gamma responses to HCV peptides was 33 days (range, 29-50 days), and these responses peaked between 180 and 360 days. Nineteen subjects had sufficient follow-up to determine outcome, with 15 (79%) developing persistent viremia and 4 (21%) clearing viremia spontaneously. Of those with progression to chronic infection and detectable T cell responses, all lost recognition of one or more antigens recognized during acute infection, and the median reduction in the magnitude of responses was 85%. Most significantly, despite ongoing viremia, those who had persistent infection did not develop new epitope specificities after the first 6 months of infection. In conclusion, in most individuals, the CD8+ T cell responses generated early in HCV infection decline in peripheral blood and are not replaced with new responses. Supplementary material for this article can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index.html). (HEPATOLOGY 2005;42:104–112.)

Ancillary